Purolite, a manufacturer of ion exchange, catalyst, adsorbent and specialty resins, and Codexis, a producer of enzymes, have partnered to develop and commercialize immobilized transaminase enzymes for use in the production of pharmaceuticals.
By binding to inert resins, the enzymes are immobilized facilitating separation from a reaction mixture and allowing for use under diverse conditions and re-use at a commercial scale.
Under the new collaboration with Purolite, a kit of immobilized transaminases will be launched as an extension of CODEX Screening Kits.
Codexis pharmaceuticals senior vice president Dr Peter Seufer-Wasserthal said, "The new immobilized enzyme kits will allow potential customers to quickly assess ideas for biocatalytic processes."
Purolite LifeTech unit business manager Dr Alessandra Basso said, "The successful implementation of these ready-to-use immobilized enzymes for fast screening processes opens the door to new concepts of drug development, where scientists who are unfamiliar with biocatalytic processes can easily apply immobilized enzymes to different screening processes that can speed up new-molecule and API development."
